Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OVR034
MIFTS: 38

Ovarian Clear Cell Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ovarian Clear Cell Adenocarcinoma

About this section

MalaCards integrated aliases for Ovarian Clear Cell Adenocarcinoma:

Name: Ovarian Clear Cell Adenocarcinoma 12 15 17 71

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:5304
NCIt 49 C40078
UMLS 71 C1518693
Sources

Summaries for Ovarian Clear Cell Adenocarcinoma

About this section
Disease Ontology : 12 A ovarian adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Ovarian Clear Cell Adenocarcinoma is related to adenocarcinoma and clear cell adenofibroma. An important gene associated with Ovarian Clear Cell Adenocarcinoma is ARID1A (AT-Rich Interaction Domain 1A), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Sunitinib and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include ovary, colon and kidney, and related phenotypes are endocrine/exocrine gland and cardiovascular system

Sources

Related Diseases for Ovarian Clear Cell Adenocarcinoma

About this section

Diseases related to Ovarian Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 120)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.3 TP53 SMAD3 PIK3CA NAPSA MET
2 clear cell adenofibroma 30.8 PIK3CA NAPSA ARID1A
3 endometriosis 30.6 PGR HOXA10 HNF1B ESR2
4 ovarian clear cell adenofibroma 30.6 PIK3CA NAPSA
5 serous cystadenocarcinoma 30.5 TP53 PIK3CA PGR ESR2 ARID1A
6 endometriosis of ovary 30.1 PGR HNF1B ESR2 ARID1A
7 cystadenocarcinoma 29.9 TP53 PIK3CA PGR ESR2
8 clear cell adenocarcinoma 29.9 TP53 SMAD3 PIK3CA PGR NAPSA HOXA10
9 ovarian serous cystadenocarcinoma 29.6 TP53 PIK3CA PGR ESR2 ARID1A
10 ovary adenocarcinoma 29.6 TP53 SMARCA4 PIK3CA PGR ARID1A
11 ovarian clear cell carcinoma 29.6 TP53 PIK3CA NAPSA MET HNF1B ARID1A
12 renal cell carcinoma, nonpapillary 29.5 TP53 PIK3CA NAPSA MTOR MET HNF1B
13 lung cancer susceptibility 3 29.1 TP53 STMN1 PIK3CA NAPSA MTOR MET
14 endometrial cancer 28.4 TP53 SMAD3 PIK3CA PGR MTOR HOXA10
15 clear cell adenocarcinoma of the ovary 12.0
16 ovarian cancer 10.5
17 rare head and neck tumor 10.5 TP53 PIK3CA
18 mucinous adenocarcinoma 10.4
19 appendix adenocarcinoma 10.4
20 ovarian epithelial cancer 10.4
21 breast squamous cell carcinoma 10.4 TP53 PIK3CA
22 rare adenocarcinoma of the breast 10.4 TP53 PIK3CA
23 adult hepatocellular carcinoma 10.4 TP53 PIK3CA
24 uterine corpus serous adenocarcinoma 10.3 TP53 PIK3CA ARID1A
25 uterine body mixed cancer 10.3 TP53 PIK3CA ARID1A
26 uterine corpus endometrial carcinoma 10.3 TP53 PIK3CA ARID1A
27 krukenberg carcinoma 10.3 NAPSA HNF1B
28 ovarian serous carcinoma 10.3
29 adenofibroma 10.3
30 dermatosis papulosa nigra 10.2 PIK3CA MTOR
31 bartholin's gland adenoma 10.2 TP53 PGR
32 neutropenia 10.2
33 bartholin's gland benign neoplasm 10.2 TP53 PGR
34 vestibular gland benign neoplasm 10.2 TP53 PGR
35 ovarian seromucinous carcinoma 10.2 TP53 PGR
36 large cell acanthoma 10.2 TP53 MTOR
37 keratosis, seborrheic 10.2 TP53 PIK3CA MTOR
38 apocrine adenosis of breast 10.2 TP53 PGR
39 endometrial clear cell adenocarcinoma 10.1 TP53 HNF1B
40 malignant epithelial tumor of ovary 10.1
41 comedo carcinoma 10.1 TP53 PGR
42 cervical clear cell adenocarcinoma 10.1 PGR NAPSA
43 carcinosarcoma 10.1 TP53 PIK3CA PGR
44 bizarre leiomyoma 10.1 TP53 PGR
45 breast sarcoma 10.1 TP53 PIK3CA PGR
46 vulvar disease 10.1 TP53 PIK3CA PGR
47 hypertrophy of breast 10.1 TP53 PIK3CA PGR
48 lobular neoplasia 10.1 TP53 PGR ESR2
49 breast malignant phyllodes tumor 10.1 TP53 PGR
50 parameningeal embryonal rhabdomyosarcoma 10.1 TP53 PIK3CA

Graphical network of the top 20 diseases related to Ovarian Clear Cell Adenocarcinoma:



Diseases related to Ovarian Clear Cell Adenocarcinoma
Sources

Symptoms & Phenotypes for Ovarian Clear Cell Adenocarcinoma

About this section

MGI Mouse Phenotypes related to Ovarian Clear Cell Adenocarcinoma:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.31 ARID1A CBX7 ESR2 HNF1B HOXA10 MET
2 cardiovascular system MP:0005385 10.3 ARID1A ESR2 GPX3 HOXA10 MET MTOR
3 growth/size/body region MP:0005378 10.29 ARID1A CBX7 ESR2 GPX3 HNF1B HOXA10
4 homeostasis/metabolism MP:0005376 10.23 ARID1A ESR2 GPX3 HNF1B MET MTOR
5 embryo MP:0005380 10.21 ARID1A HNF1B MET MTOR PGR PIK3CA
6 muscle MP:0005369 10.1 ARID1A ESR2 HNF1B MET MTOR PGR
7 nervous system MP:0003631 10.1 ARID1A ESR2 GPX3 HOXA10 MET MTOR
8 limbs/digits/tail MP:0005371 10.03 ESR2 HOXA10 MET PGR SFRP5 SMAD3
9 neoplasm MP:0002006 10.02 ARID1A CBX7 ESR2 MET PGR PIK3CA
10 normal MP:0002873 9.85 ARID1A ESR2 MAP4 MET MTOR PGR
11 no phenotypic analysis MP:0003012 9.8 ARID1A ESR2 MET MTOR PGR PIK3CA
12 renal/urinary system MP:0005367 9.61 ANXA4 ESR2 GPX3 HNF1B MET MTOR
13 skeleton MP:0005390 9.28 ARID1A ESR2 HOXA10 MTOR PGR PIK3CA
Sources

Drugs & Therapeutics for Ovarian Clear Cell Adenocarcinoma

About this section

Drugs for Ovarian Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
2 Angiogenesis Inhibitors Phase 2
3 Protein Kinase Inhibitors Phase 2
4
Paclitaxel Approved, Vet_approved 33069-62-4 36314
5 Albumin-Bound Paclitaxel

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
2 A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma Active, not recruiting NCT00979992 Phase 2 Sunitinib Malate
3 Retrospective Multi-institutional Survey of Clinical Characteristics in Ovarian Clear Cell Adenocarcinoma Cancer Patients Completed NCT02129036

Search NIH Clinical Center for Ovarian Clear Cell Adenocarcinoma

Sources

Genetic Tests for Ovarian Clear Cell Adenocarcinoma

About this section
Sources

Anatomical Context for Ovarian Clear Cell Adenocarcinoma

About this section

MalaCards organs/tissues related to Ovarian Clear Cell Adenocarcinoma:

40
Ovary, Colon, Kidney, Skin, Cervix
Sources

Publications for Ovarian Clear Cell Adenocarcinoma

About this section

Articles related to Ovarian Clear Cell Adenocarcinoma:

(show top 50) (show all 138)
# Title Authors PMID Year
1
Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. 61
29979406 2018
2
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. 61
29933751 2018
3
Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. 61
29184869 2017
4
[Ovarian Cancer Rupture Causing Acute Abdomen That Required Emergency Surgery - A Case Report]. 61
28133347 2016
5
Rare and challenging case of stroke as a manifestation of non bacterial thrombotic endocarditis in an underlying ovarian clear cell carcinoma. 61
27833758 2016
6
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. 61
27660815 2016
7
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. 61
27699033 2016
8
Spheroid cancer stem cells display reprogrammed metabolism and obtain energy by actively running the tricarboxylic acid (TCA) cycle. 61
27120812 2016
9
ARID1A gene mutation in ovarian and endometrial cancers (Review). 61
26572704 2016
10
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. 61
26397155 2015
11
Optimal cytoreductive surgery for underlying ovarian cancer associated with deep venous thrombosis without placement of inferior vena cava filter: A case report and literature review. 61
26622893 2015
12
The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma. 61
25855053 2015
13
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. 61
25398420 2015
14
[A Case of Pneumocystis Pneumonia during Chemotherapy for Recurrent Ovarian Cancer]. 61
26197755 2015
15
Napsin A is a specific marker for ovarian clear cell adenocarcinoma. 61
24721826 2015
16
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. 61
25658832 2015
17
Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas. 61
25755836 2015
18
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. 61
26082939 2014
19
Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma. 61
25275661 2014
20
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy]. 61
25434451 2014
21
Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines. 61
25083560 2014
22
A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. 61
24306200 2014
23
Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. 61
24987918 2014
24
Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. 61
24375438 2014
25
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. 61
24815386 2014
26
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. 61
24707459 2014
27
Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature. 61
24669262 2014
28
Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. 61
24459582 2014
29
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. 61
24504419 2014
30
Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. 61
23805888 2013
31
[A patient with recurrent ovarian clear cell adenocarcinoma and chronic kidney disease exhibited complete response to paclitaxel plus carboplatin]. 61
24196084 2013
32
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. 61
23430509 2013
33
Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial. 61
23899586 2013
34
Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma. 61
23726144 2013
35
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. 61
23502469 2013
36
Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. 61
23469222 2013
37
Stathmin Regulates Hypoxia-Inducible Factor-1α Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma. 61
23819061 2013
38
Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. 61
24244679 2013
39
Clear cell carcinoma of the female genital tract (not everything is as clear as it seems). 61
22885379 2012
40
[Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors]. 61
23159083 2012
41
Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma. 61
22871047 2012
42
Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma. 61
22498943 2012
43
[DNA damage response in ovarian clear cell adenocarcinoma]. 61
22812231 2012
44
Two cases of ovarian clear cell adenocarcinoma producing estradiol. 61
22360511 2012
45
Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture. 61
22317866 2012
46
Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. 61
22101352 2012
47
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. 61
22120431 2012
48
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. 61
21983935 2012
49
Re-expression of estrogen receptor β inhibits the proliferation and migration of ovarian clear cell adenocarcinoma cells. 61
21874257 2011
50
Hepatocyte nuclear factor-1β expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis. 61
21496868 2011
Sources

Variations for Ovarian Clear Cell Adenocarcinoma

About this section
Sources

Expression for Ovarian Clear Cell Adenocarcinoma

About this section
Search GEO for disease gene expression data for Ovarian Clear Cell Adenocarcinoma.
Sources

Pathways for Ovarian Clear Cell Adenocarcinoma

About this section

Pathways related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 36
12.46 TP53 SMAD3 PIK3CA MTOR MET ESR2
2
Glioma 36
Show member pathways
 12.43 TP53 PIK3CA MTOR MET ESR2
3
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.31 TP53 PIK3CA MTOR MET
4
MicroRNAs in cancer 36
12.26 TP53 STMN1 PIK3CA MTOR MET
5
Apoptosis Pathway 70
Show member pathways
 12.23 TP53 PIK3CA MTOR MET
6
Development IGF-1 receptor signaling 22
Show member pathways
 12.18 TP53 PIK3CA MTOR MET
7
Proteoglycans in cancer 36
12.07 TP53 PIK3CA MTOR MET
8
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.04 TP53 PIK3CA MTOR MET
9
Gastric cancer 36
Show member pathways
 11.94 TP53 SMARCA4 SMAD3 PIK3CA PGR MTOR
10
Cellular senescence (KEGG) 36
11.91 TP53 SMAD3 PIK3CA MTOR
11
Senescence and Autophagy in Cancer 1
11.77 TP53 SMAD3 MTOR
12
Type II diabetes mellitus 36 1
Show member pathways
 11.69 PIK3CA MTOR HNF1B
13
TGF-beta Signaling Pathways 64
11.68 SMAD3 MTOR ESR2
14
Pathways Affected in Adenoid Cystic Carcinoma 1
11.47 TP53 PIK3CA ARID1A
15
Central carbon metabolism in cancer 36
11.1 TP53 PIK3CA MTOR MET
16
Ovarian Infertility Genes 1
11 SMAD3 PGR ESR2
17
Extracellular vesicle-mediated signaling in recipient cells 1
10.81 SMAD3 MTOR MET
Sources

GO Terms for Ovarian Clear Cell Adenocarcinoma

About this section

Cellular components related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.28 TP53 SMARCA4 SMAD3 PGR HOXA10 HNF1B
2 nBAF complex GO:0071565 9.26 SMARCA4 ARID1A
3 transcription factor complex GO:0005667 9.26 TP53 SMAD3 HOXA10 HNF1B
4 npBAF complex GO:0071564 9.16 SMARCA4 ARID1A

Biological processes related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10 TP53 SMARCA4 SMAD3 PGR MET HOXA10
2 regulation of transcription by RNA polymerase II GO:0006357 9.95 TP53 SMARCA4 SMAD3 HNF1B ARID1A ANXA4
3 positive regulation of transcription, DNA-templated GO:0045893 9.91 TP53 SMARCA4 SMAD3 HNF1B ESR2 ARID1A
4 wound healing GO:0042060 9.72 TP53 SMAD3 MTOR
5 regulation of epithelial cell proliferation GO:0050678 9.56 SMAD3 PGR
6 negative regulation of cell growth GO:0030308 9.56 TP53 SMARCA4 SMAD3 ESR2
7 negative regulation of macroautophagy GO:0016242 9.54 PIK3CA MTOR
8 gastrulation GO:0007369 9.54 TP53 SMAD3 ARID1A
9 hepatocyte growth factor receptor signaling pathway GO:0048012 9.52 STMN1 MET
10 anoikis GO:0043276 9.51 PIK3CA MTOR
11 negative regulation of transcription by RNA polymerase II GO:0000122 9.5 TP53 SMARCA4 SMAD3 HNF1B ESR2 CBX7
12 positive regulation of transcription of nucleolar large rRNA by RNA polymerase I GO:1901838 9.49 SMARCA4 MTOR
13 negative regulation of guanyl-nucleotide exchange factor activity GO:1905098 9.4 STMN1 MET
14 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.33 TP53 SMARCA4 SMAD3
15 negative regulation of thrombin-activated receptor signaling pathway GO:0070495 9.32 STMN1 MET
16 liver development GO:0001889 8.92 SMAD3 PIK3CA MET HNF1B

Molecular functions related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.09 WT1-AS TP53 STMN1 SMARCA4 SMAD3 PIK3CA
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.73 TP53 SMAD3 PGR HOXA10 HNF1B ESR2
3 identical protein binding GO:0042802 9.5 TP53 SMAD3 PGR MTOR MET ESR2
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.1 TP53 SMARCA4 SMAD3 PGR HOXA10 ESR2
Sources

Sources for Ovarian Clear Cell Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....